Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular eve...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Transl Med
Hlavní autoři: Bovijn, Jonas, Krebs, Kristi, Chen, Chia-Yen, Boxall, Ruth, Censin, Jenny C., Ferreira, Teresa, Pulit, Sara L., Glastonbury, Craig A., Laber, Samantha, Millwood, Iona Y., Lin, Kuang, Li, Liming, Chen, Zhengming, Milani, Lili, Smith, George Davey, Walters, Robin G., Mägi, Reedik, Neale, Benjamin M., Lindgren, Cecilia M., Holmes, Michael V.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116615/
https://ncbi.nlm.nih.gov/pubmed/32581134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aay6570
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky